02:32 , May 18, 2018 |  BC Week In Review  |  Financial News

Xenikos raises $30M series B for GVHD

Xenikos B.V. (Nijmegen, the Netherlands) raised $30 million in a tranched series B round co-led by new investors Medicxi and RA Capital. In early 2019, the company plans to start Phase III testing in the...
22:12 , May 15, 2018 |  BC Extra  |  Financial News

Xenikos raises $30M series B

Xenikos B.V. (Nijmegen, the Netherlands) raised $30 million in a series B round co-led by new investors Medicxi and RA Capital. In early 2019, the company plans to start Phase III testing in the U.S....
18:54 , Mar 15, 2018 |  BC Innovations  |  Product R&D

Engineered to kill

Nkarta Inc. is betting that boosting NK cells’ intrinsic ability to discriminate between cancer and healthy cells will increase their efficacy as anti-cancer agents and lower their risk of toxicity compared with the more common...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
23:02 , Nov 17, 2016 |  BC Innovations  |  Product R&D

Hemorrhaging targets

An analysis of the almost 5,000 abstracts set to be presented at the 2016 American Society of Hematology (ASH) meeting next month indicates this year’s hot topics in preclinical research include a spattering of new...
08:00 , Dec 10, 2012 |  BioCentury  |  Emerging Company Profile

Xenikos: Dual attack in GvHD

Xenikos B.V. 's T-Guard, a mAb-toxin fusion protein that blocks activation of T cells associated with graft-versus-host disease, is being developed to provide faster symptom relief and better safety than high-dose corticosteroids now used in...
07:00 , Jun 25, 2012 |  BC Week In Review  |  Financial News

Xenikos completes venture financing

Xenikos B.V. , Nijmegen, the Netherlands   Business: Transplant   Date completed: 6/19/12   Type: Venture financing   Raised: €3.6 million ($4.6 million)   Investors: Sanquin Blood Supply Foundation; Participatiemaatschappij Oost Nederland; Innovation & Investment...
00:47 , Jun 20, 2012 |  BC Extra  |  Financial News

Xenikos raises EUR 3.6 million

Xenikos B.V. (Nijmegen, the Netherlands) raised EUR 3.6 million ($4.6 million) in a series A round from Sanquin Blood Supply Foundation; Participatiemaatschappij Oost Nederland; and Innovation & Investment Fund Gelderland. Xenikos also secured a EUR...
08:00 , Mar 2, 2009 |  BC Week In Review  |  Company News

Celerus sales and marketing update

Celerus launched 12 antibodies to be used on its Celerus Wave System for immunohistochemistry analysis. The antibodies target CD7, CD8 , neutral endopeptidase (MME) (NEP) (CD10) , CD30 , CD34, CD79a, c-kit proto-oncogene protein (KIT,...
07:00 , Aug 21, 2008 |  BC Innovations  |  Tools & Techniques

Interfering with HIV

A team of Korean and American researchers has shown in a humanized mouse model that small interfering RNA-based therapeutics could be harnessed to treat HIV. 1 However, because administering these therapeutics would require repeated i.v....